Skip to main menu Skip to main content Skip to footer
neurotech logo Accessibility Menu
  • About Us
    • Our Team
      • Leadership Team
      • Board of Directors
      • Medical Advisory Board
    • Careers
    • Contact Us
  • Our Product
  • Science & Technology
    • Publications
  • Clinical
  • Patients
  • News

Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel) 

Home » Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel) 

Press Release – Update on Biologics License Application (BLA)